Tracking infections |
Professor Derrick Crook from our Experimental Medicine division tells us about his research on tracking infections |
Derrick Crook |
|
|
Why we work on Alzheimer’s disease |
Housed within the Target Discovery Institute, the Alzheimer’s Research UK Oxford Drug Discovery Institute (ODDI) juxtaposes drug discovery expertise alongside scientific and academic understanding of patients, disease mechanisms and model systems. |
John Davis |
|
|
X-rays for drug discovery |
Professor Frank von Delft works to ensure that X-ray structures can serve as a routine and predictive tool for generating novel chemistry for targeting proteins. |
Frank von Delft |
|
|
From information to structure |
Dr Brian Marsden aims to make structural and chemical biology data accessible to non-experts, by providing computational resources including data management, sample tracking, in silico modelling support plus provision of public access to SGC data. |
Brian Marsden |
|
|
Unravelling proteins |
Dr Nicola Burgess-Brown heads the Biotechnology Group at the SGC, which generates proteins suitable for structural and functional studies. |
Nicola Burgess-Brown |
|
|
Targeting drug discovery |
The development of new medicines is dependent on the identification of novel drug targets. |
Kilian Huber |
|
|
Understanding growth signals |
Growth hormones and cytokines regulate the key physiological processes of growth and differentiation as well as responses to injury and infection. |
Alex Bullock |
|
|
Inflammation in disease |
The main aim of Dr Xue's research is to understand the molecular and cellular mechanisms mediating inflammatory diseases, and to translate their findings into therapeutic concepts to treat these diseases. |
Luzheng Xue |
|
|
A deep breath in |
Asthma and COPD (chronic obstructive pulmonary disease) are common conditions that affect the lives of many people. |
Mona Bafadhel |
|
|
Chemistry, epigenetics and drugs |
Alteration of gene expression is fundamental to many diseases. A better understanding of how epigenetic proteins affect diseases provides a starting point for therapy development and the discovery of new drug. |
Paul Brennan |
|
|
The genetics of metabolic diseases |
A missing step in a metabolic pathway leads to the build-up of toxic compounds, and the lack of materials essential for normal function. |
Wyatt Yue |
|
|
Biological imaging |
Video microscopy aims to improve target discovery and drug development and to do so generates large volumes of data. |
Jens Rittscher |
|
|
Pharmacogenomics |
Dr Sebastian Nijman develops new approaches to study signalling networks in cancer cells and uncover specific weaknesses, particularly in breast and lung cancer. This can be used to develop more effective drugs and to better guide treatment decisions. |
Sebastian Nijman |
|
|
SHARP |
Lowering cholesterol in chronic kidney disease |
Colin Baigent |
|
|
Wider Statin Use Saves Lives |
Wider Statin Use Saves Lives |
Colin Baigent |
|
|
Asthma |
Airway inflammation |
Ian Pavord |
|
|
The Global Health Network |
Dr Trudie Lang tells us how the Global Health Network facilitates collaboration and resource sharing. |
Trudie Lang |
|
|
Respiratory Medicine |
Dr Najib Rahman talks about his research on respiratory medicine. |
Najib Rahman |
|
|
Development of chemical probes |
Professor Stefan Knapp tells us how the development of chemical probes helps us to find new drugs. |
Stefan Knapp |
|
|
Membrane proteins and drug development |
Dr Liz Carpenter talks about her research on membrane proteins and drug development. |
Liz Carpenter |
|
|
Clinical Trials in Gastroenterology |
Dr Simon Travis tells us how clinical trials bring tomorrow's treatments to patients today. |
Simon Travis |
|
|
Proteomics and Biomarkers |
Dr Benedikt Kessler tells us how proteomics helps find biomarkers. |
Benedikt Kessler |
|
|
Drug Discovery |
Professor Chas Bountra explains how new drugs can offer novel treatments for neurodegenerative and gastrointestinal diseases, as well as pain disorders. |
Chas Bountra |
|
|